Novo Nordisk Abandons Rare-Disease Factory for Warehouse Push as Canada Opens Door to Semaglutid Gen
Dr. Reddy’s launches generic semaglutide in Canada, breaching Novo Nordisk’s exclusivity. Novo shifts $1.33B plant to warehouse, as…
Novo Nordisk Scraps Rare-Disease Plant and Unleashes High-Dose Data to Fortify GLP-1 Empire
Novo Nordisk shifts focus to weight-loss drugs, converting a rare-disease factory into GLP-1 warehousing. Q1 earnings beat estimates…
Novo Nordisk Scraps Rare-Disease Factory, Bets on Oral Obesity Pill and CagriSema to Revive Growth
Novo Nordisk pivots from rare diseases to obesity, scrapping a Danish plant and 400 jobs, as it races…
Novo Nordisk Broadens GLP 1 Story With Pediatric And Rare Disease Gains
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…